AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome.
- These boron-based molecules were originally discovered by researchers at Anacor Pharmaceuticals, Inc. (a wholly owned subsidiary of Pfizer) and the University of Georgia, with grant funding from Wellcome.
- The lead compound under this series, AN2-502998 (formerly known as AN15368), was discovered in close collaboration with Professor Rick Tarleton, Ph.D., University of Georgia, an expert in Chagas disease and Trypanosoma cruzi biology.
- To date, preclinical activities have been supported using non dilutive grant funding from Wellcome and are conducted in partnership with Professor Tarleton.
- I am optimistic that AN2-502998 has the potential to be a solution for those infected with T. cruzi and at risk for development of debilitating and life-threatening Chagas disease.”